Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San Diego, CA.
The presentation, titled “Therapeutic Antibodies to Complex Receptors – Exploring the Urokinase Plasminogen Activator Receptor” will take place at 2:15 p.m. PST on December 7, 2022.
“Elevated levels of soluble urokinase plasminogen activator receptor (suPAR) inflame kidney tissues leading to cellular stress, damaged kidney cells, and compromising kidney structure and function. Walden is directly targeting this causal agent driving renal disease to provide a truly novel and disease-modifying approach that has the potential to transform the treatment of kidney diseases”, stated Dr. Duncan. “suPAR is well-suited to antibody targeting and we have validated it with human genetics, human therapeutic data, and with animal disease model data. We now look forward to bringing our suPAR program into human clinical development in early 2023.”
About Walden Biosciences
Cryptocurrency Litigation - Yesterday, Today, and Tomorrow
"It's a Mobile World" - Using Asterisk to Distribute Calls in a Mobile-first Retail Environment